Longeveron Inc. (LGVN)Healthcare | Biotechnology | Miami, United States | NasdaqCM
6.72 USD
-0.08
(-1.176%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 6.72 |
Hot Take ↕ | Aug. 22, 2026, 3:23 a.m. EDT
The investment case for this biotechnology firm has collapsed under the weight of a catastrophic multi-year decline. While the recent price action shows a modest bounce off the lows, the underlying reality is stark: the stock has lost nearly 98% of its value over the last four years, with the last three consecutive years seeing double-digit percentage drops. This is not a temporary correction; it is a structural implosion driven by a -90% crash in 2024 and a -69% drop in 2025, signaling that the market has thoroughly rejected the company's current trajectory and clinical trial designs. Fundamentally, the business is bleeding cash with negative operating margins, shrinking revenues, and no path to profitability visible in the forward estimates. The lack of a dividend is unsurprising given the burn rate, leaving shareholders with zero income and significant capital risk. Despite the optimistic analyst targets which seem detached from the harsh reality of the balance sheet and recent performance, the data suggests a deep value trap where the price reflects a permanent impairment of the business model rather than a bargain opportunity. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.185524 |
| MSTL | 0.197201 |
| AutoARIMA | 0.197765 |
| AutoETS | 0.197765 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 11.31 |
| Ljung-Box p | 0.789 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 32.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.585 |
| Revenue per Share | 0.492 |
| Market Cap | 21,424,684 |
| Forward P/E | -4.39 |
| Beta | -0.25 |
| Previous Name | Longeveron LLC |
| Website | https://longeveron.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1727494 |
| Address1 | Life Science & Technology Park |
| Address2 | Suite 520 1951 NW 7th Avenue |
| All Time High | 4,500.0 |
| All Time Low | 4.75 |
| Ask | 8.66 |
| Ask Size | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 90,164 |
| Average Daily Volume3 Month | 39,733 |
| Average Volume | 39,733 |
| Average Volume10Days | 90,164 |
| Beta | -0.248 |
| Bid | 5.22 |
| Bid Size | 2 |
| Book Value | 0.328 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.72 |
| Current Ratio | 2.629 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.2323 |
| Day Low | 6.5501 |
| Debt To Equity | 5.585 |
| Display Name | Longeveron |
| Earnings Call Timestamp End | 1,786,566,600 |
| Earnings Call Timestamp Start | 1,786,566,600 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -22,440,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.532 |
| Enterprise To Revenue | 10.049 |
| Enterprise Value | 11,928,691 |
| Eps Forward | -1.53 |
| Eps Trailing Twelve Months | -9.87 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.0482 |
| Fifty Day Average Change | -0.32820034 |
| Fifty Day Average Change Percent | -0.046565127 |
| Fifty Two Week Change Percent | -17.27494 |
| Fifty Two Week High | 12.3 |
| Fifty Two Week High Change | -5.5800004 |
| Fifty Two Week High Change Percent | -0.45365855 |
| Fifty Two Week Low | 4.75 |
| Fifty Two Week Low Change | 1.9699998 |
| Fifty Two Week Low Change Percent | 0.4147368 |
| Fifty Two Week Range | 4.75 - 12.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,613,140,200,000 |
| Float Shares | 2,569,305 |
| Forward Eps | -1.53 |
| Forward P E | -4.3921566 |
| Free Cashflow | -11,603,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 38 |
| Fullday Change | -0.0800004 |
| Fullday Change Percent | -1.17648 |
| Fullday Price | 6.72 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.69755995 |
| Gross Profits | 828,000 |
| Has Pre Post Market Data | 1 |
| Implied Shares Outstanding | 3,188,197 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,787,788,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. |
| Long Name | Longeveron Inc. |
| Market | us_market |
| Market Cap | 21,424,684 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_410711455 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -23,474,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 21,679,739 |
| Number Of Analyst Opinions | 3 |
| Open | 6.8 |
| Operating Cashflow | -20,374,000 |
| Operating Margins | -21.501741 |
| Payout Ratio | 0.0 |
| Phone | 844 470 2550 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.72 |
| Post Market Time | 1,787,959,804 |
| Prev Name | Longeveron LLC |
| Previous Close | 6.8 |
| Price Hint | 2 |
| Price To Book | 20.487804 |
| Price To Sales Trailing12 Months | 18.049438 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.355 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.0800004 |
| Regular Market Change Percent | -1.17648 |
| Regular Market Day High | 7.2323 |
| Regular Market Day Low | 6.5501 |
| Regular Market Day Range | 6.5501 - 7.2323 |
| Regular Market Open | 6.8 |
| Regular Market Previous Close | 6.8 |
| Regular Market Price | 6.72 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 79,668 |
| Return On Assets | -0.90949994 |
| Return On Equity | -2.0360801 |
| Revenue Growth | -0.092 |
| Revenue Per Share | 0.492 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,043,297 |
| Shares Percent Shares Out | 0.0533 |
| Shares Short | 169,994 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 153,123 |
| Short Name | Longeveron Inc. |
| Short Percent Of Float | 0.057800002 |
| Short Ratio | 5.06 |
| Source Interval | 15 |
| State | FL |
| Symbol | LGVN |
| Target High Price | 104.5 |
| Target Low Price | 30.0 |
| Target Mean Price | 71.5 |
| Target Median Price | 80.0 |
| Total Cash | 10,077,000 |
| Total Cash Per Share | 3.161 |
| Total Debt | 581,000 |
| Total Revenue | 1,187,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.2102 |
| Two Hundred Day Average Change | -0.49020004 |
| Two Hundred Day Average Change Percent | -0.067987025 |
| Type Disp | Equity |
| Volume | 79,668 |
| Website | https://longeveron.com |
| Zip | 33,136 |